Video

Incentives for Filing a Product Through the 351(k) Pathway

Steven Lucio of Novation discusses how Teva's Granix (tbo-filgrastim), which was filed through a 351(a) pathway, was approved for only 1 indication--and it was not the indication considered to be the "most definitive" for that particular product.

Steven Lucio of Novation discusses how Teva's Granix (tbo-filgrastim), which was filed through a 351(a) pathway, was approved for only 1 indication--and it was not the indication considered to be the "most definitive" for that particular product. As a result, uptake of this product may be affected, says Lucio. Conversely, within the 351(k) structure, companies would potentially be able to extrapolate across indications.

This video was shot at the 2013 Academy of Managed Care Pharmacy in San Antonio, Texas.

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Related Videos
Psychiatric pharmacist and patient -- Image credit: NanSan | stock.adobe.com
Psychiatric pharmacist -- Image credit: HBS | stock.adobe.com
Hematology -- Image credit: DIgilife | stock.adobe.com
Image credit:  Artur | stock.adobe.com
Cardiovascular disease doctor or cardiologist holding red heart in clinic or hospital exam room office for csr professional medical service, cardiology health care and world heart health day concept - Image credit: Chinnapong | stock.adobe.com
Image credit: AwieDarwis | stock.adobe.com
Image credit: viperagp | stock.adobe.com
Image credit:  kitsawet | stock.adobe.com